• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超越免疫抑制:促肿瘤髓系细胞在乳腺癌中的多面功能

Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast Cancers.

作者信息

Blaye Céline, Boyer Thomas, Peyraud Florent, Domblides Charlotte, Larmonier Nicolas

机构信息

Centre National de la Recherche Scientific (CNRS) Unité Mixte de Recherche (UMR) 5164, ImmunoConcEpT, Bordeaux, France.

Department of Medical Oncology, Institut Bergonié, Bordeaux, France.

出版信息

Front Immunol. 2022 Mar 3;13:838040. doi: 10.3389/fimmu.2022.838040. eCollection 2022.

DOI:10.3389/fimmu.2022.838040
PMID:35309358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8927658/
Abstract

Breast cancers are commonly associated with an immunosuppressive microenvironment responsible for tumor escape from anti-cancer immunity. Cells of the myeloid lineage account for a major part of this tumor-promoting landscape. These myeloid cells are composed of heterogeneous subsets at different stages of differentiation and have traditionally been described by their cardinal ability to suppress innate and adaptive anticancer immunity. However, evidence has accumulated that, beyond their immunosuppressive properties, breast cancer-induced myeloid cells are also equipped with a broad array of "non-immunological" tumor-promoting functions. They therefore represent major impediments for anticancer therapies, particularly for immune-based interventions. We herein analyze and discuss current literature related to the versatile properties of the different myeloid cell subsets engaged in breast cancer development. We critically assess persisting difficulties and challenges in unequivocally discriminate dedicated subsets, which has so far prevented both the selective targeting of these immunosuppressive cells and their use as potential biomarkers. In this context, we propose the concept of IMCGL, "pro-tumoral immunosuppressive myeloid cells of the granulocytic lineage", to more accurately reflect the contentious nature and origin of granulocytic cells in the breast tumor microenvironment. Future research prospects related to the role of this myeloid landscape in breast cancer are further considered.

摘要

乳腺癌通常与免疫抑制性微环境相关,这种微环境导致肿瘤逃避免疫抗癌作用。髓系细胞在这种促进肿瘤生长的环境中占主要部分。这些髓系细胞由处于不同分化阶段的异质亚群组成,传统上根据其抑制先天性和适应性抗癌免疫的主要能力来描述。然而,越来越多的证据表明,除了其免疫抑制特性外,乳腺癌诱导的髓系细胞还具有广泛的“非免疫性”促进肿瘤生长的功能。因此,它们是抗癌治疗的主要障碍,尤其是基于免疫的干预措施。我们在此分析和讨论与参与乳腺癌发展的不同髓系细胞亚群的多功能特性相关的当前文献。我们批判性地评估了在明确区分特定亚群方面仍然存在的困难和挑战,这迄今为止既阻碍了对这些免疫抑制细胞的选择性靶向,也阻碍了它们作为潜在生物标志物的应用。在此背景下,我们提出了IMCGL的概念,即“粒细胞系促肿瘤免疫抑制性髓系细胞”,以更准确地反映乳腺肿瘤微环境中粒细胞的争议性质和来源。进一步考虑了与这种髓系环境在乳腺癌中的作用相关的未来研究前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fad/8927658/a749356ec3f4/fimmu-13-838040-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fad/8927658/8a68b6cc9d2f/fimmu-13-838040-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fad/8927658/a749356ec3f4/fimmu-13-838040-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fad/8927658/8a68b6cc9d2f/fimmu-13-838040-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fad/8927658/a749356ec3f4/fimmu-13-838040-g002.jpg

相似文献

1
Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast Cancers.超越免疫抑制:促肿瘤髓系细胞在乳腺癌中的多面功能
Front Immunol. 2022 Mar 3;13:838040. doi: 10.3389/fimmu.2022.838040. eCollection 2022.
2
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.通过化疗和靶向治疗调节免疫抑制性肿瘤微环境,以增强免疫治疗效果。
Oncoimmunology. 2022 Sep 13;11(1):2120676. doi: 10.1080/2162402X.2022.2120676. eCollection 2022.
3
Chemotherapeutic targeting of cancer-induced immunosuppressive cells.癌症诱导免疫抑制细胞的化学治疗靶向。
Cancer Res. 2014 May 15;74(10):2663-8. doi: 10.1158/0008-5472.CAN-14-0301. Epub 2014 Apr 28.
4
Myeloid cells in circulation and tumor microenvironment of breast cancer patients.乳腺癌患者循环系统和肿瘤微环境中的髓样细胞。
Cancer Immunol Immunother. 2017 Jun;66(6):753-764. doi: 10.1007/s00262-017-1977-z. Epub 2017 Mar 10.
5
Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.利用髓系细胞中的免疫检查点进行癌症免疫治疗。
Cancer Lett. 2019 Jun 28;452:51-58. doi: 10.1016/j.canlet.2019.03.018. Epub 2019 Mar 22.
6
Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment.抑制性髓系细胞塑造肿瘤免疫微环境。
Adv Biol (Weinh). 2021 Mar;5(3):e1900311. doi: 10.1002/adbi.201900311. Epub 2021 Feb 11.
7
Complement activation in cancer: Effects on tumor-associated myeloid cells and immunosuppression.补体激活在癌症中的作用:对肿瘤相关髓系细胞和免疫抑制的影响。
Semin Immunol. 2022 Mar;60:101642. doi: 10.1016/j.smim.2022.101642. Epub 2022 Jul 14.
8
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.癌症免疫治疗的新时代:靶向髓系来源抑制细胞以克服免疫逃逸。
Front Immunol. 2020 Jul 30;11:1680. doi: 10.3389/fimmu.2020.01680. eCollection 2020.
9
Aberrant PGE₂ metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells.膀胱肿瘤微环境中异常的 PGE₂ 代谢促进肿瘤浸润髓系细胞的免疫抑制表型。
Int Immunopharmacol. 2011 Jul;11(7):848-55. doi: 10.1016/j.intimp.2011.01.033. Epub 2011 Feb 11.
10
Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment.针对肿瘤相关中性粒细胞的靶向治疗和利用以增强癌症治疗的免疫疗法和药物递送。
Cancer Biol Med. 2020 Feb 15;17(1):32-43. doi: 10.20892/j.issn.2095-3941.2019.0372.

引用本文的文献

1
Topohistology of dendritic cells and macrophages in the distal and proximal nodes along the lymph flow from the lung.沿肺淋巴引流方向,远端和近端淋巴结中树突状细胞和巨噬细胞的局部组织学
J Anat. 2025 Mar 28. doi: 10.1111/joa.14251.
2
Exploration of plasma tryptophan levels along with Ki-67 expression binomial investigation for forecasting tumor aggressiveness within invasive ductal breast cancer.探索血浆色氨酸水平以及Ki-67表达二元分析以预测浸润性导管癌的肿瘤侵袭性。
J Mol Histol. 2024 Dec 21;56(1):52. doi: 10.1007/s10735-024-10333-y.
3
Myeloid‑derived suppressor cells as targets of emerging therapies and nanotherapies (Review).

本文引用的文献

1
Tumor-Infiltrating Neutrophils and Non-Classical Monocytes May Be Potential Therapeutic Targets for HER2 Gastric Cancer.肿瘤浸润中性粒细胞和非经典单核细胞可能是HER2阳性胃癌的潜在治疗靶点。
Immune Netw. 2021 Aug 20;21(4):e31. doi: 10.4110/in.2021.21.e31. eCollection 2021 Aug.
2
Bone marrow cells are differentiated into MDSCs by BCC-Ex through down-regulating the expression of CXCR4 and activating STAT3 signalling pathway.骨髓细胞通过 BCC-Ex 下调 CXCR4 的表达并激活 STAT3 信号通路分化为 MDSCs。
J Cell Mol Med. 2021 Jun;25(12):5497-5510. doi: 10.1111/jcmm.16559. Epub 2021 May 6.
3
A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast.
髓源性抑制细胞作为新兴疗法和纳米疗法的靶点(综述)
Med Int (Lond). 2024 Jun 25;4(5):46. doi: 10.3892/mi.2024.170. eCollection 2024 Sep-Oct.
4
Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity.激素受体信号与乳腺癌对抗肿瘤免疫的抵抗。
Int J Mol Sci. 2023 Oct 10;24(20):15048. doi: 10.3390/ijms242015048.
5
Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA.α-TEA 增强免疫检查点阻断的抗肿瘤疗效。
Front Immunol. 2023 Feb 22;14:1057702. doi: 10.3389/fimmu.2023.1057702. eCollection 2023.
人类乳腺正常、癌前病变和肿瘤发生状态的单细胞 RNA 表达图谱。
EMBO J. 2021 Jun 1;40(11):e107333. doi: 10.15252/embj.2020107333. Epub 2021 May 5.
4
The Next Decade of Immune Checkpoint Therapy.免疫检查点治疗的下一个十年。
Cancer Discov. 2021 Apr;11(4):838-857. doi: 10.1158/2159-8290.CD-20-1680.
5
STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.沉默 STAT3 和激活 TLR7/8 通路重极化并抑制乳腺癌患者来源的髓系抑制细胞。
Front Immunol. 2021 Feb 19;11:613215. doi: 10.3389/fimmu.2020.613215. eCollection 2020.
6
Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation.组织蛋白酶 C 通过调节中性粒细胞浸润和中性粒细胞胞外诱捕网形成促进乳腺癌肺转移。
Cancer Cell. 2021 Mar 8;39(3):423-437.e7. doi: 10.1016/j.ccell.2020.12.012. Epub 2021 Jan 14.
7
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌(KEYNOTE-355):一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
8
Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumption.4T1 乳腺癌肿瘤 T 细胞微环境促使树突状细胞向破骨细胞样 APC 分化,从而增强骨质消耗。
Bone. 2021 Feb;143:115755. doi: 10.1016/j.bone.2020.115755. Epub 2020 Nov 18.
9
Tumor-Secreted GRP78 Promotes the Establishment of a Pre-metastatic Niche in the Liver Microenvironment.肿瘤分泌的 GRP78 促进肝微环境中前转移龛的建立。
Front Immunol. 2020 Sep 29;11:584458. doi: 10.3389/fimmu.2020.584458. eCollection 2020.
10
Breast Cancer Cell-Neutrophil Interactions Enhance Neutrophil Survival and Pro-Tumorigenic Activities.乳腺癌细胞与中性粒细胞的相互作用增强中性粒细胞存活及促肿瘤活性。
Cancers (Basel). 2020 Oct 8;12(10):2884. doi: 10.3390/cancers12102884.